Furthermore, several case studies have documented SS induced by interferon therapy.28–30 Thus, type I interferon may serve as a unifying factor in SS, suggesting that US Food and Drug Administration–approved Janus kinase–signal transducer and activator of transcription (JAK/STAT) inhibitors, which block type I interferon signaling, could be a new therapeutic strategy. Here, SOAT1 is linked to synovial sarcoma.